Clinical Trial

Rectal Cancer Neoadjuvant Therapy-Real World Study

Study acronym: RC-NAT-RWS
Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to utilise a real-world data platform to integrate multi-omics data-including radiomics, gut microbiota, pathological quality control and liquid biopsy-to construct a multidimensional predictive model for the efficacy of rectal cancer treatment following neoadjuvant therapy. By integrating multimodal data, the study aims to accurately assess the efficacy of neoadjuvant therapy and identify patients suitable for a 'watch-and-wait' strategy, thereby achieving tumour control and preserving organ function without the need for surgery. Furthermore, it seeks to provide scientific evidence for the efficacy of the 'watch-and-wait' strategy and the selection of optimal timing for surgery, whilst validating the model's effectiveness and assessing its clinical feasibility through prospective clinical trials.
Trial Details
NCT Number NCT07566559
Lead Sponsor Beijing Friendship Hospital
Conditions Rectal Cancer
Enrollment 869 participants
Start Date 2025-01-01
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-05